Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.605 USD | +3.05% |
|
+11.67% | +25.29% |
09/07 | Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant | CI |
01/07 | Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.29% | 227.78Cr | |
+62.26% | 86TCr | |
+38.95% | 63TCr | |
-4.01% | 36TCr | |
+15.56% | 32TCr | |
+9.02% | 30TCr | |
+5.89% | 23TCr | |
+16.53% | 23TCr | |
+16.10% | 18TCr | |
+2.31% | 16TCr |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Transcript : Amneal Pharmaceuticals, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-07-2019 through Jan-10-2019